Amgen Inc. (NASDAQ:AMGN) Shares Sold by Greenwood Gearhart Inc.

Greenwood Gearhart Inc. decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 752 shares of the medical research company’s stock after selling 42 shares during the quarter. Greenwood Gearhart Inc.’s holdings in Amgen were worth $242,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. First Horizon Advisors Inc. lifted its position in shares of Amgen by 3.2% during the 3rd quarter. First Horizon Advisors Inc. now owns 60,769 shares of the medical research company’s stock valued at $19,581,000 after buying an additional 1,872 shares in the last quarter. Napa Wealth Management acquired a new position in Amgen during the third quarter worth $1,104,000. HighVista Strategies LLC acquired a new position in Amgen during the third quarter worth $3,255,000. Swiss National Bank lifted its holdings in Amgen by 0.3% during the third quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company’s stock valued at $513,033,000 after purchasing an additional 5,500 shares in the last quarter. Finally, Summit Trail Advisors LLC raised its position in shares of Amgen by 40.1% during the 3rd quarter. Summit Trail Advisors LLC now owns 7,552 shares of the medical research company’s stock worth $2,433,000 after purchasing an additional 2,163 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $277.63 on Tuesday. The company has a fifty day moving average of $305.69 and a two-hundred day moving average of $315.66. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. Amgen Inc. has a 1 year low of $257.80 and a 1 year high of $346.85. The company has a market capitalization of $149.23 billion, a PE ratio of 35.55, a P/E/G ratio of 3.02 and a beta of 0.55.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the prior year, the business earned $4.96 EPS. Amgen’s quarterly revenue was up 23.2% compared to the same quarter last year. As a group, analysts expect that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 9th. Investors of record on Monday, November 18th were issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.24%. The ex-dividend date was Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Analyst Ratings Changes

AMGN has been the topic of several research reports. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. Sanford C. Bernstein started coverage on shares of Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price for the company. Finally, Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and lifted their target price for the company from $320.00 to $333.00 in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $323.05.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.